Allocord Market Report 2026

Allocord Market Overview

• The Allocord market growth in the historic period has been driven by limited treatment options for scid, reliance on bone marrow transplantation • Market expansion is supported by increasing diagnosis of inherited immunodeficiencies, expansion of advanced biologic therapies • Growth Driver: Rising Chronic Diseases Boost Allocord Market Via Regenerative Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Allocord Market?

Allocord is a therapeutic product designed for the treatment of severe combined immunodeficiency (SCID) and other rare genetic disorders, formulated to provide essential enzyme replacement therapy. It is used to manage these conditions by replenishing the deficient enzyme needed for proper immune system function. The main types of formulations of allocord are injectable suspension and cryopreserved units. Injectable suspension is a liquid-based cord blood product designed for direct administration to patients requiring regenerative or therapeutic treatments. It is used for indications such as hematopoietic disorders, immunologic disorders, inherited disorders, and acquired disorders. The users of allocord include adult patients, pediatric patients, and geriatric patients, and distributed by various channels such as hospitals and clinics as well as retail and specialty pharmacies.

What Is The Allocord Market Growth Forecast?

The growth in the forecast period can be attributed to increasing diagnosis of inherited immunodeficiencies, expansion of advanced biologic therapies, growth in specialty treatment centers, rising healthcare funding for rare diseases, improved long term patient outcomes. Major trends in the forecast period include rising use of cellular and enzyme therapies, expansion of treatment for severe immunodeficiency, growing adoption in rare genetic disorders, increased focus on personalized immune therapies, strengthening of hospital based specialty care.

Global Allocord Market Segmentation

1) By Formulation: Injectable Suspension, Cryopreserved Units 2) By Clinical Indication: Hematopoietic Disorders, Immunologic Disorders, Inherited Disorders, Acquired Disorders 3) By End User: Adult Patients, Pediatric Patients, Geriatric Patients 4) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies

What Are The Drivers Of The Allocord Market?

The rising prevalence of chronic diseases is expected to propel the growth of the allocord market going forward. Chronic diseases refer to a group of long-lasting health conditions that typically progress slowly and persist over time, often requiring ongoing management. Rising chronic disease cases are due to unhealthy lifestyles, socioeconomic disparities, aging populations, and urbanization impacting access to health resources. Allocord contributes to addressing the rising prevalence of chronic diseases by offering cord blood banking services, enabling access to stem cell-based regenerative therapies and innovative treatment options for managing these conditions. For instance, in April 2024, according to Allergy UK, a UK-based national charity, more than 21 million people in the UK are affected by allergies, which became the most commonly reported chronic health condition in 2022, and projections indicate that by 2026, half of Europe's population will experience at least one allergy. Therefore, the rising prevalence of chronic diseases is driving the growth of the allocord industry. Increasing interest in personalized medicine is expected to boost the allocord market going forward. Personalized medicine refers to a healthcare approach that tailors medical treatment and prevention strategies to individual genetic, environmental, and lifestyle factors. Increasing interest in personalized medicine is driven by advancements in genomics, precision diagnostics, growing chronic disease prevalence, and demand for more effective, tailored healthcare solutions. Allocord supports the growing interest in personalized medicine by providing cord blood banking services that enable access to stem cells for customized regenerative therapies and targeted treatments. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, increasing interest in personalized medicine is driving the allocord industry. The rising healthcare expenditure is expected to bolster the growth of the allocord market going forward. Healthcare expenditure refers to the total amount spent on health services and related activities within a certain period, typically measured annually. Rising healthcare expenditure is due to an aging population, chronic diseases, higher service prices, increased demand, technological advancements, rising drug costs, the COVID-19 impact, medical inflation, and income polarization. Allocord supports rising healthcare expenditure by offering cord blood banking services that enable advanced regenerative therapies, contributing to innovative and cost-effective treatment options. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure will drive the growth of the allocord industry.

Key Players In The Global Allocord Market

Major companies operating in the allocord market are SSM Cardinal Glennon Children's Medical Center

Regional Insights

North America was the largest region in the allocord market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Allocord Market?

The allocord market consists of sales of hematopoietic progenitor cell (HPC) products, cord blood injectable suspension, and cryopreserved cord blood units. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Allocord Market Report 2026?

The allocord market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the allocord industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.